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Abstract  
Chronic Obstructive Pulmonary Disease (COPD) is a common preventable disease characterized by 
an inflammatory infiltrate of the airways and progressive airflow obstruction. Whilst many 
inflammatory cells are implicated in COPD, the neutrophil is by far the most abundant and has been 
extensively associated with disease pathogenesis. Neutrophil products are thought to be key 
mediators of inflammatory changes in the airways of COPD patients, causing pathological changes 
such as emphysema and hypersecretion of mucus. Furthermore, both bacterial colonization and 
acute exacerbations of COPD are associated with increased neutrophil numbers and markers of 
activation, further highlighting their role in disease. 
High rates of bacterial colonization and infective causes of acute exacerbations are observed in some 
patients with COPD despite this abundance of anti-bacterial neutrophils, raising the suggestion that 
neutrophil functions may be impaired in COPD. Exploring this hypothesis is complicated by the wide 
variety of functions exhibited by the neutrophil; impairment of any one of these could result in 
impaired bacterial clearance.  
There is a need for new therapeutic strategies in COPD.  Further explorations into neutrophil 
function in both health and COPD is allowing us to understand its role in disease pathogenesis and to 
elucidate whether this key inflammatory mediator represents a viable therapeutic target to prevent 
disease progression. 
  
Introduction 
 
Chronic Obstructive Pulmonary Disease (COPD) remains a significant global health challenge.  It has 
not seen the same improvements in morbidity and mortality as many other chronic inflammatory 
diseases and only one novel drug class has reached market in the past twenty years(1).  After 25 
years of smoking approximately 30 – 40% of adults will have developed COPD(2) but despite most 
patients having this shared risk factor, COPD is heterogeneous in presentation, age of onset and 
speed of decline. Whilst the disease is defined by the presence of airflow obstruction, patients can 
be divided into recognized clinical phenotypes. These include those with a predominance of 
emphysema(3), obstructive bronchiolitis (3, 4), the presence or absence of chronic bronchitis, 
evidence of bacterial colonisation of the lower airways with potentially pathogenic bacteria, those 
who experience frequent exacerbations(5) and those who experience a faster decline in lung 
function(6). Clinical phenotypes are stable within individual patients(6) and cluster within families(7) 
and thus are likely to reflect genetic traits.  Indeed, genome wide association studies in COPD have 
identified a large number of signals for genes associated with lung development, lung parenchyma 
formation and repair and epigenetic regulation such as the inositol phosphate pathway(8, 9).   These 
studies suggest there may be a wide range of therapeutic targets in different subsets of COPD 
patients, providing hope for personalised medicine.  However drug development is costly and there 
are concerns about the affordability of targeting many different molecules for small groups of 
patients,  especially in low income countries where the burden of COPD is rising fastest(10).  This 
raises the question as to whether there might be a more common targetable mechanism across 
disease phenotypes which could provide a treatment for larger number of patients. 
Inflammation in COPD 
Most pro-inflammatory mediators and immune cells have been shown to be raised in lung secretions 
taken from patients with COPD(11) and this inflammation is heightened and self-sustaining in 
smokers who are susceptible to COPD in contrast to those smokers who are not (12, 13).   However, 
while many cells and mediators have been implicated in COPD pathogenesis at some level, few have 
reliably demonstrated their importance as therapeutic targets in human studies.  For example, 
despite the promising resistance to COPD-like lung damage shown by TNFα receptor (14) or IL-1 
receptor 1 knock-out mice (15) studies targeting these individual mediators in unselected cohorts of 
patients with COPD have been disappointing with TNFα and IL-1 receptor 1 inhibition showed no 
improvements in disease endpoints(16, 17).  This might suggest that, unlike murine models, only sub 
groups of patients will respond to individual mediator-based therapies.  In support of this concept, 
there is variability in inflammatory patterns between patients, even when matched for age, smoking 
status and disease severity(18) which might reflect specific genetic traits as shown in some studies of 
TNFα (19) and IL-1β (20) polymorphisms.   
To complicate matters further, there is significant intra-patient variability in the concentration of 
plasma and sputum mediators and cells on a day to day basis.   Some mediators increase while 
others decrease suggesting the variability not only reflects dilution but also fluctuations in the 
specific components of the inflammatory load (18, 21).  This supports an alternative explanation to 
the negative trial results reported to date, where there is so much redundancy, compensation and 
overlap within the complex inflammatory storm that is established COPD(22) that end-cell effects 
can be driven by an alternative cytokine, should one be abrogated.  For example, toll-like receptors, 
TNFα and IL-1 signalling to NF-κB all converge on a common IκB kinase complex that phosphorylates 
the NF-κB inhibitory protein IκBα, despite the upstream signalling components being to a large part 
receptor-specific(23). The effects of these mediators are synergistic and inhibiting one has not 
proved efficacious enough to impact robustly on cellular inflammation or COPD disease progression.  
Potentially targeting the functions of the end-cell and not the intermediatory cytokine might be 
more effective and there is a strong rationale for targeting the neutrophil in COPD. 
Classical neutrophil functions in health  
Neutrophils are the most abundant leukocyte, accounting for 70% of all circulating white blood cells. 
They are short-lived cells (with a half-life of around eight hours) with basal production of 1-2 x 1011 
neutrophils/day in health; though this can increase to 1012 during infection(24-26). Following 
myeloblastic differentiation in the bone marrow, the mobilisation of terminally differentiated 
neutrophils into the circulation is tightly controlled by bone marrow signals and circulating growth 
factors including those between neutrophil CXCR4 and  bone marrow stromal cell CXCL12 causing 
cell retention and neutrophil CXCR2 resulting in neutrophil release(27, 28). Neutrophils are 
characterised by the presence of a multi-lobed nucleus and granular cytoplasm, due to the presence 
of Azurophillic (primary), Specific (secondary) and Gelatinase (tertiary) granules, as well as secretory 
vesicles.   These granules and vesicles contain a complex and specialised arsenal of proteins which 
facilitate neutrophil migration from the systemic circulation through the dense extracellular matrix 
to areas of inflammation, and then permit microbial killing and tissue remodelling and degradation, 
as listed in Table 1. This is not an “all or nothing response” and neutrophils require different levels of 
activation (and subsequent calcium mobilisation) to release granules, with secretory vesicles 
requiring the least stimulation, mobilising to facilitate migration and adhesion, while azurophil 
granules (which are the most cytotoxic) requiring the most stimulation. 
Table 1.  The contents of human neutrophil granules and secretory vesicles 
Constituents Azurophil Specific Gelatinase Secretory 
Matrix proteins Elastase 
Proteinase 3 
Cathepsin G 
Cathepsin D 
Defensins 
Lysozyme 
Myeloperoxidase 
Bacterial permeability increasing 
protein (BPI) 
Azuricidin 
α1-antitrypsin 
β-glucoronidase 
Phospholipase A2 
Collagenase 
Gelatinase 
hCAP-18 
Histaminase 
Heprainase 
Lactoferrin 
Lyoszyme 
NGAL 
β2 microglobulin 
 
 
Gelatinase 
Lysosyme 
β2 microglobulin 
 
 
Plasma proteins 
Membrane 
proteins 
CD63 
CD68 
Presenilin 1 
V-type H+-ATPase 
CD11b/CD18 
Cytochrome b558 
fMLP-R 
G-proteinα-
subunit 
Leukolysin 
VAMP-2 
CD11b/CD18 
Cytochrome b558 
fMLP-R 
VAMP-2 
V-type H+-ATPase 
 
Alkaline 
phosphatase 
CD11b/CD18 
CD16 
CD10 
CD13 
CD14 
fMLP-R 
C1q-R 
Cytochrome b558 
Legend. The contents of the different sub-types of neutrophil granule, divided into membranous and matrix (cytosolic) 
proteins.  R, receptor; hCAP-18, human cathelicidin protein; VAMP-2, vesicle-associated membrane protein 2. fMLP, N-
formylmethionyl-leucyl-phenylalnine 
Neutrophils are guided towards inflammation in a gradient-dependent manner by chemotactic 
signals (30). Circulating neutrophils cross the endothelium at sites of inflammation via the Leukocyte 
Adhesion Cascade (LAC), whereby neutrophils interact with endothelial cells at sites of high 
inflammatory signalling, facilitating passage across the endothelium and stimulating signalling 
cascades within the neutrophil associated with antimicrobial armament and activation. It is unclear 
whether the LAC occurs in the pulmonary circulation however, due to the small diameter of the 
capillaries found there, which may influence neutrophil function (31). 
Neutrophil homeostasis is also regulated by signals from tissue resident macrophages. When 
neutrophils become activated they release IL23 which stimulates IL-17 production. IL-17 induces 
release of G-CSF, causing further mobilisation of neutrophils into the blood stream to assist with 
clearing an infection (19,20). 
Changing perceptions of the neutrophil 
Neutrophils in COPD 
Neutrophils are considered central to the pathogenesis of COPD.  Airway neutrophilia is a feature of 
COPD regardless of the clinical phenotype, severity of disease, rapidity of decline or age of onset. 
Their numbers and products in sputum and airway lavage fluid correlate with disease severity, 
evident in the degree of airway obstruction, decline in FEV1 and severity of emphysema present (32-
35). Within the airway wall, confirmation of a neutrophilic presence has been more enigmatic, with 
some studies confirming(36) and others refuting their presence (37).  However, neutrophils are not 
tissue resident, and inconsistencies could reflect the short life span of these cells.  To address this, 
studies have focused on tissue collection at times of significant neutrophil recruitment to the 
airways in COPD (during acute exacerbations), and here numbers have been shown to be 
consistently raised (38).  Increased levels of human neutrophil lipocalin (HNL) and myeloperoxidase 
(MPO), products of neutrophils degranulation, in the sputum of COPD patients suggest increased 
neutrophil activity in COPD airways (39). Concordantly, 18-fluorodeoxyglucose positron emission 
tomography studies of neutrophilic inflammation in COPD show enhanced uptake in the 
emphysematous regions of the lungs and correlate with measures of disease severity (40). Elegant 
pathological studies by Hogg et al suggest small airways dysfunction and destruction may precede 
the development of emphysema and airflow obstruction, and may reflect the earliest pathological 
changes in the lungs of patients with COPD (41). Neutrophils have also been implicated here, 
showing a relationship with neutrophilic infiltration and tomographic measures of air trapping (42).   
 
 
 
Neutrophils and co-morbidities of COPD 
 
Potential targets and therapeutic challenges – CXCR2 data. From trial 
   
 
Activated neutrophils degranulate during migration towards inflammation and infection, during 
frustrated phagocytosis and NETosis, releasing serine proteases and elastolytic enzymes (e.g. 
neutrophil elastase [NE], matrix metalloproteases [MMPs] 8 and 9, proteinase-3) into the airways of 
COPD patients (43, 44). Excessive activity of these enzymes in COPD airways is thought to degrade 
elastin and type III collagen, leading to destruction of alveolar tissue and consequently centrilobular 
emphysema, apparent in many cases of COPD (43, 44).  Serine proteases are also potent stimulants 
of mucus secretion in the airways, and cigarette smoke is thought to have direct effects on cilia, 
shortening them and reducing mucociliary clearance (45-47). The esulting mucus accumulation 
further obstructs the airways and increasing the risk of bacterial colonisation, contributing to the 
inflammatory environment (45, 48). Figure 1 summarizes the inflammatory interactions thought to 
underlie COPD.   
Alveolar macrophages also contribute to and may orchestrate this inflammatory milieu by the 
release of inflammatory mediators and macrophage-specific and scavenged proteinases, recruiting 
more neutrophils to the airways, which in turn promote monocyte recruitment, thus leading to a 
vicious cycle of inflammatory damage.  
COPD is also associated with a number of chronic inflammatory co-morbidities, including 
cardiovascular disease, type 2 diabetes, osteoporosis and periodontitis; greater prevalence of these 
co-morbidities are seen in COPD patients even once contributory factors (such as age, smoking and 
sedentary lifestyle) have been taken into account. It has been hypothesized that the pulmonary 
inflammation present in COPD may “overspill” systemically, leading to the development of different 
co-morbidities (with the type most likely dependent on individual susceptibility and exposures). 
Interestingly, many of the co-morbidities shared with COPD are also characterized by neutrophilic 
inflammation. For example, neutrophil products are raised acutely following a myocardial infarction 
and predict outcomes(49), neutrophil receptor expression and function are altered in diabetes(50), 
neutrophil lymphocyte ratios are inversely related to bone density in elderly people(51) and 
neutrophilic inflammation appears central to the development of periodontitis(52).  
As demonstrated in figure 1, macrophages(53), T cells(54), B cells and auto-immunity(54, 55), and 
eosinophils(56) are all implicated in COPD. The degree to which a certain cell is involved in individual 
patients may reflect varying genetic predispositions or environmental exposures which drive disease 
within that individual. However, just as with each clinical phenotype, and with the majority of co-
morbidities associated with COPD, no matter what cell type has been implicated neutrophils remain 
at the heart of the disease. In the landmark paper by Brightling discussing eosinophilic signals in 
COPD(56), average airway cells constituted of 2.4% eosinophils, 21.5% macrophages, 0.4% T-
lymphocytes and 67.9% neutrophils. 
The association between COPD and neutrophils is further evidenced by Alpha-1 Antitrypsin 
Deficiency (AATD). Alpha-1 Anti-trypsin is an anti-protease that directly antagonizes the proteolytic 
activities of NE on a one to one molar basis, and is thought to provide greater than 90% of the 
protective mechanisms against NE in the lungs (44, 57, 58). AATD is the most extensively 
documented genetic risk factor for COPD,  where the inhibition of NE proteolysis predisposes to 
increased NE-mediated degradation of extracellular matrix and development of emphysema (58).  
Emphysema occurs even in the absence of smoking in some individuals and rates of decline in lung 
function are faster in those who smoke. Furthermore, there is evidence that emphysema 
progression is slowed by augmentation with replacement Alpha-1 Anti-trypsin(59) although the 
effect of augmentation on FEV1 decline is less clear(60). 
Of note, the persistently progressive and self-perpetuating inflammatory pattern observed in ex-
smoking patients who develop COPD is not observed in ex-smokers who do not develop COPD(61, 
62), suggesting a differential inflammatory response in individuals who are susceptible to disease in 
comparison to those who are not. Furthermore, only 25-50% of smokers develop COPD(63) and 
COPD also occurs in non-smokers(64), hence chronic exposure to cigarette smoke is neither 
sufficient alone to cause disease nor necessary for disease development, and other factors must play 
a role in disease development. In keeping with this, familial and genome association studies support 
the presence of a number of inherited traits that either promote or protect the host from COPD (65). 
Our current understanding of these traits is limited because genetic studies have not identified 
polymorphisms that are common in a large proportion of COPD patients.  Furthermore, there is 
evidence that lung development (with early childhood and potentially in utero stimuli) contributes 
to disease burden (66). This has led to the orphan disease hypothesis of COPD(67); many potential 
genetic drivers and developmental factors, combined with the appropriate environment trigger, lead 
to the clinical symptoms and airflow obstruction that defines disease. Such a diverse array of 
potential susceptibility factors is challenging, both in terms of understanding disease pathogenesis 
and developing treatment strategies, and there is great interest in finding a unifying therapeutic 
target for the highest number of patients. The neutrophil may represent such a potential candidate 
target for therapeutic modulation. 
Bacterial Colonisation and Acute Exacerbations 
Bacterial colonisation of the lower respiratory tract is common in COPD; approximately 20-30% of 
stable COPD patients have a positive bacterial sputum culture and 60% show evidence of lower 
respiratory tract bacteria using culture independent assays. Bacterial colonisation correlates with 
more severe airflow obstruction, a more pronounced decline in lung function, worse health status 
and increased incidence of acute exacerbations (68-73). Bacterial colonisation is also associated with 
worsened pathological changes: increases in inflammatory cytokines are associated with neutrophil 
recruitment (such as IL-8 and LTB4) and activation (TNFα), increased mucus secretion(74), reduced 
ciliary beat frequency(75), and epithelial damage(76, 77).  
Many sufferers of COPD experience acute periods of exacerbation of respiratory symptoms, thought 
to be partly caused by an increase in the inflammatory infiltrate of the airways. For the majority of 
exacerbations (as high as 78%), this is induced by bacterial or viral infection, although many patients 
suffer exacerbations in the absence of identified infection (78-80). Acute exacerbations of COPD are 
significant medical events, often resulting in hospitalisation and occasionally mortality (81). 
Irrespective of aetiology, airway neutrophilia shows a clear increase during exacerbations of COPD 
(38, 82). There is also evidence of increased matrix metalloproteinase-9 (MMP-9) activity, the 
neutrophil proteolytic enzyme (44). Furthermore, increased airway neutrophilia appears to be 
associated with critical expiratory flow limitation, dynamic lung hyperinflation, and consequently 
increased respiratory distress (68, 78, 83).   
Neutrophil Functions in Health and COPD 
Not all smokers develop COPD even when matched for exposure and there are differences in 
neutrophilic inflammatory burden in ex-smokers with and without COPD, therefore differential 
neutrophil functions are implicated in COPD pathogenesis. 
Once within inflamed tissue, the neutrophil utilizes chemotactic gradients created by host-derived 
inflammatory cytokines (e.g. IL-8) and bacterial products (e.g. Lipopolysaccharide [LPS], N-formyl-
methionyl-leucyl-phenylalanine [fMLP]) released from the site of infection, to migrate towards 
invading pathogens (30). These chemoattractant molecules bind their cognate receptors inducing 
functional changes in the neutrophil (30) such as the assembly of oxidative burst machinery (84). 
External gradients are amplified within the cell, allowing accurate mobilisation of internal structures 
(pseudopods for migration, granules for phagolysis) towards the inflammatory or infectious insult 
and facilitating full use of functions such as phagocytosis, production of toxic oxidative products, 
release of bactericidal granular proteins and production of neutrophil extracellular traps (NETs) (30). 
The neutrophil granule system is designed to store highly toxic substances within the cell, facilitating 
fast release in response to invading pathogens (29). Granules are traditionally divided into four sub-
types: azurophilic (primary)(29, 85) and specific (secondary)(29, 86, 87) granules contain 
predominantly bactericidal products (e.g. myeloperoxidase, α-defensins, lactoferrin), whereas 
gelatinase (tertiary)(30, 88) granules and secretory vesicles(89-91) contain products that aid 
neutrophil migration and endothelial transmigration (e.g. metalloproteases [MMPs], β2-integrins, 
FcγIII [CD16]). Different granule sub-types are mobilized and released dependent on cytosolic free 
calcium levels, which allows coordination of granule release to match cellular requirement, for 
example mobilisation of azurophilic granules occurs only once the neutrophil comes into contact 
with a pathogen (92). Details of the contents of neutrophil granules are provided in table 1 (29). 
Reactive Oxygen Species (ROS) are released both into phagosomes and externally during migration, 
degranulation and NETosis (see later). NADPH oxidase acts as a channel for electrons from the 
cytosol into phagosomal vacuoles, stimulating reduction of oxygen (O2) to the superoxide anion O2- 
(93). Superoxide can then dismutate, a process accelerated by the enzyme superoxide dismutase 
(SOD), to form the highly oxidative hydrogen peroxide (H2O2), which can react further (the MPO-
halide-hydrogen peroxide antibacterial system) to form strongly bactericidal hypohalous acids (e.g. 
HOCl) (85, 94-98). The role of ROS and the NADPH oxidase in elimination of pathogens is long-
believed to be a dominant killing mechanism in neutrophils, however the exact role of these 
processes in neutrophil bacterial killing has come under recent scrutiny with some research 
supporting their role as facilitatory rather than obligatory (96). 
Phagocytosis is an active, receptor-dependent process through which a phagocyte internalizes 
material into membrane-bound vacuoles (99). Direct interactions between neutrophilic pattern 
recognition receptors (PRRs) and surface-expressed pathogen-associated molecular patterns 
(PAMPs) can generate signalling cascades that lead to ingestion of the target pathogen, a process 
termed ‘unopsonized’ phagocytosis (30, 100, 101). Phagocytosis of opsonized particles is a much 
faster process; ingestion of an IgG-opsonized particles by a neutrophil can take less than 20 seconds 
(102). The most extensively studied opsonin receptors of neutrophils, the Fc receptors (e.g. FcγRIIA 
[CD32], FcγIIIb [CD16]) bind IgG-bound particles triggering a signalling cascade involving the tyrosine 
kinase Syk and phosphatidylinositol 3-kinase (PI3K). Complement molecules also opsonize pathogens 
to phagocytic killing by interacting with neutrophil complement receptors (e.g. CR1 [CD35], CR3 
[CD11b/CD18]) (103-106). Binding activates a signalling cascade involving phospholipase D (PLD), 
diacylglycerol (DAG) and the GTPase Rho. Both IgG and complement mediated phagocytosis result in 
cytoskeletal rearrangements that facilitate particle ingestion (107, 108).  
Phagosome maturation refers to the equipping of the nascent phagosome with the antimicrobial 
potential required to eliminate a pathogen (103). Unlike the unquestionable acidification observed 
in the macrophage phagosome(103, 109), the neutrophil phagosome undergoes a transient 
alkalisation, despite evidence of V-ATPase proton-pumping activity, and antimicrobial activity is 
thought to be predominantly acquired through delivery of neutrophil granules and the NADPH 
oxidase machinery (30, 110, 111). Membrane trafficking supports the controlled delivery of 
bactericidal granular proteins into the phagosome (92, 112). These processes are depicted in Figure 
2.  
Neutrophils are also able to produce extracellular traps (NETs), consisting of a backbone of 
uncondensed chromatin to which bactericidal products such as cathepsins, MPO and nuclear 
histones are bound (113). Microscopic studies suggest NETs are responsible for the killing of a wide 
range of pathogens, including Gram-negative(113) and Gram-positive(113, 114) bacteria as well as 
fungi(115), however the process of NETosis occurs later in neutrophil activation than other killing 
processes such as phagocytosis or generation of ROS (116). NETs may also have detrimental effects 
on the host by exposing host molecules (i.e. DNA) within regions of active inflammation, introducing 
risk of autoimmunity. NETs have been implicated in cases of systemic lupus erythematosus (SLE), 
sepsis-induced hepatotoxicity and deep vein thrombosis (117-120). 
There is a paradox that airway secretions from patients with COPD are neutrophil replete, 
correlating closely with disease severity, but that airway colonisation and infections are common 
(43, 121-123). Hence, it is likely that neutrophils present in COPD airways are impaired, weakening 
antimicrobial function and contributing to lung damage, and there is evidence supporting this 
hypothesis. COPD neutrophils demonstrate migratory inaccuracy, able to migrate towards 
chemotactic signals with greater speed, but decreased accuracy and velocity than neutrophils from 
age-matched healthy controls (124, 125). In vitro modelling suggests this results in a longer and 
more convoluted migratory path, increased secretion of damaging digestive enzymes and a delay in 
bacterial killing processes, potentially responsible for the increased rates of bacterial colonisation 
and infective exacerbations observed in COPD patients (124). Flow cytometric studies demonstrate 
enhanced respiratory burst in neutrophils of COPD sufferers as compared to healthy smokers(126), 
and furthermore increased markers of oxidative activity both in COPD airways and systemically 
suggest increased ROS-producing capacity in stable disease (127). Evidence in acute exacerbations is 
less clear, with some studies(128) suggesting the ‘frequent exacerbator’ phenotype of COPD 
demonstrates decreased oxidative burst in comparison to both healthy controls and stable COPD 
patients, and others demonstrating increased oxidative burst in active exacerbations (129, 130). 
Similarly, there is conflicting evidence of NETosis; increased quantities of NETs and NET-producing 
neutrophils are observed in the sputum of both stable and exacerbating COPD patients(131, 132), 
however when isolated from blood, neutrophils of exacerbating patients demonstrate attenuated 
NET-producing ability (133). A potential explanation for this is an impaired clearance of NETs by 
DNAses(119) rather than increased production, but this is currently unexplored. The efferocytosis 
function of alveolar macrophages however, which mediates clearance of neutrophils(134), is 
thought to be impaired in COPD (135). The resulting accumulation of dead neutrophils in the airways 
may lead to secondary necrosis and excessive release of neutrophil granules and pro-inflammatory 
cytokines, contributing to an increasing neutrophilic infiltration and promoting an inflammatory 
environment (135, 136). There is limited data about the phagocytic functions of COPD neutrophils. 
Ingestion of opsonized E. coli and Candida species have been found to be reduced in COPD 
neutrophils compared to age-matched healthy controls (137, 138).  However, neither Venge et al. 
nor Muns et al. observed any difference between the phagocytic abilities of COPD neutrophils and 
controls(139, 140), suggesting any defect may be both stimulant and assay dependent.  
If neutrophil functions are dysregulated in COPD, favouring inflammation but impeding bacterial 
clearance, understanding the reasons for this is crucial to allow treatment. Genome wide studies 
have not consistently shown polymorphisms in pathways implicated in neutrophil functions, 
suggesting there are no common neutrophil-based genetic disorders causing COPD. However, 
transcriptional changes in neutrophil genotype have recently been described that appear to effect 
function in lupus patients(141), and it may be that the combination of multiple genetic factors, in 
themselves insufficient to cause disease, lead to epigenetic changes in neutrophils following 
environmental exposures which lead to long-term alterations in gene expression, perpetuating the 
inflammatory damage seen in COPD.  Understanding these changes may unlock new strategies for 
COPD treatment. 
Conclusion 
Neutrophils are innate immune cells that have been widely implicated in the pathogenesis of COPD. 
They are a feature of all disease phenotypes and neutrophilic inflammation is described in many of 
the shared co-morbidities. Their ability to damage lung parenchyma as part of the inflammatory 
pathology of COPD has been well-described and there is mounting evidence of neutrophil 
dysfunction in COPD, which might explain the continued inflammatory response. All these data 
suggest the neutrophil may represent a unifying therapeutic target in COPD, but the necessary 
functions of these cells make this target a challenging one. Normalizing their activity whilst 
maintaining their ability to participate in host defence may be a crucial step in preventing COPD 
progression.   
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Figure Legends 
Figure 1 Inflammatory Airways of COPD.  Inhaled irritants such as cigarette smoke induce inflammation in 
the airways, the degree of which is affected by lung development and epigenetic factors (A). Cigarette smoke 
stimulates release of cytokines from bronchial epithelial cells (B), including TGF-β which induces excessive 
collagen production from fibroblasts and consequently fibrosis of the small airways (C). Bronchial epithelial 
cells are also thought to recruit eosinophils to the airways via release of IL-33, although the exact role of the 
eosinophil in COPD is unclear (D). Alveolar macrophages are activated both by direct interactions with 
cigarette smoke and through cytokine signalling from bronchial epithelial cells (E). As well as further 
recruitment of circulating monocytes (F), alveolar macrophages work with bronchial epithelial cells to recruit 
neutrophils in vast quantities (G). Neutrophils, aided by alveolar macrophages, secrete proteolytic and 
elastolytic enzymes (H) that mediate destruction of alveolar parenchyma (I) and induce hypersecretion of mucus 
within the airways (J), both contributing to airway obstruction. It has also been hypothesized that this pulmonary 
inflammation ‘overspills’ systemically (K), resulting in associated inflammatory co-morbidities, for example 
diabetes, myocardial infarction (MI) and reduction in bone density. 
Figure 2 Phagosome Maturation. The neutrophil NADPH oxidase machinery, activated by delivery of its 
membrane-bound components to the phagosome, pumps electrons into the phagosomal space to generate toxic 
ROS. Membrane trafficking allows delivery of primary and secondary granules to the phagosomal membrane, 
which release a variety of microbicidal proteins into the phagosomal space. MPO released from primary 
granules reacts with ROS to further produce highly toxic substances . Adapted from(112). All abbreviations 
given in text if appropriate. 
 
